IBIO iBio, Inc. Insider Trading

Chief Legal Officer Banjak Marc buys 13,934 shares at $1.65 blended average; stock down -62.0% from 52-week high, -38.7% in 30 days.

Marc Banjak, Chief Legal Officer, executed two separate purchases totaling 13,934 shares for $23,055.09 on 2026-03-26, increasing his holdings from 11,066 to 25,000 shares (+125.9%). The purchases occurred at prices of $1.64 and $1.76, as the stock trades at current price $1.76 amid steep declines: -62.0% from its 52-week high and -38.7% over the past 30 days. iBio is unprofitable with net income of $-8,993,000.00 over its most recent full fiscal year, though annual revenue growth reached +77.8%. The broader context shows a cluster buy pattern with 2 other insiders also purchasing within the past 14 days, and Banjak's own cross-ticker trade history (1 prior buy) recorded a -55.5% average 90-day return with a 0.00% 90-day win rate. This purchase follows substantial downward price momentum and occurs alongside peer insider activity, but the company's unprofitable status and the insider's poor historical timing on similar transactions warrant careful scrutiny of the underlying drivers.

Brenner Martin buys 12,336 IBIO shares at $2.02; holdings rise 67.4%, but prior IBIO buy (Jan 2025) declined 55.5% over 90 days.

Brenner Martin purchased 12,336 shares at $2.02 on 2026-03-19, increasing holdings from 18,316 to 30,652 shares—a 67.4% increase. This follows a prior purchase at the same ticker on 2025-01-10 that returned +36.8% over 30 days but -55.5% over 90 days, indicating poor long-term timing on his last IBIO entry. iBio is unprofitable (net income $-9.0M) with zero latest-quarter revenue, though annual revenue grew 77.8%. The current price of $2.21 is down 7.1% over 30 days and -52.3% from the 52-week high of $4.63. The insider's cross-ticker track record shows a 0.00% win rate on 90-day returns, raising questions about whether this accumulation reflects conviction or pattern-driven behavior without favorable outcomes.

CFO Duran Felipe purchased 24,835 shares of IBIO at $2.02 (total $50.1K), tripling his position to 36.0K shares post-transaction.

Duran Felipe, the Chief Financial Officer, acquired 24,835 shares at $2.02 on 2026-03-19, representing a +223.0% increase to his post-transaction holdings of 35,974 shares. The purchase occurred at a 52.3% discount to the 52-week high of $4.63, and the stock is currently down 7.1% over the past 30 days. However, his cross-ticker track record shows mixed results: 1 prior buy averaged +36.8% at 30 days but -55.5% at 90 days, with a 0.00% 90-day win rate, and his same-ticker history at IBIO (1 prior trade) followed the same pattern—that earlier buy was not well-timed at the 90-day mark. The company remains unprofitable with net income of -$8,993,000.00 over its most recent full fiscal year, though it posted +77.8% annual revenue growth. The significant holding increase merits attention against this backdrop of prior underperformance and ongoing losses.

Director Parada Antonio Bernardino Guimaraes bought 183.8K shares of IBIO at $2.72 on 2025-01-10 ($500.0K); 6 other insiders also bought within 14 days

Director Parada Antonio Bernardino Guimaraes purchased 183,823 shares for $499,998.56 on 2025-01-10, establishing a first-time position in iBio, Inc. This acquisition is part of a broader cluster pattern: 6 other insiders made purchases within the preceding 14 days. The context is material: iBio is unprofitable with net income of $-4.0M in its latest full fiscal year, zero revenue in the latest quarter, and a market cap of $22.7M. The current stock price of $2.48 is 38.9% below its 52-week high of $4.06, though the 30-day change shows the stock up 7.4%. The convergent purchasing by multiple insiders during a period of elevated share price volatility and weak fundamentals suggests coordinated management action, though the financial condition of the company and absence of revenue warrant careful scrutiny of the underlying rationale for these purchases.

CLO Banjak Marc buys 9,191 shares at $2.72; 6 insiders bought in 14 days amid cluster pattern at unprofitable $22.7M-cap biotech.

Banjak Marc, Chief Legal Officer, purchased 9,191 shares at $2.72 on 2025-01-10, expanding his holdings from 1,875 shares (1.9K) to 11,066 shares (11.1K) — a +490.2% increase. This transaction occurred as part of a cluster buy pattern: 6 other insiders also bought within the past 14 days. The purchase occurred in a company with zero revenue in the latest quarter and a net income of $-3,989,000.00 ($-4.0M), with a market cap of $22,690,685.60 ($22.7M). The stock is currently trading 38.9% below its 52-week high of $4.06, though it has gained 7.4% over the past 30 days.

Director Arkowitz bought 18,382 shares of iBio at $2.72 on 2025-01-10; 6 other insiders also bought within 14 days amid $-4.0M net loss.

Director Arkowitz purchased 18,382 shares at $2.72, initiating a new position valued at $49,999.04 total. The transaction is part of a cluster pattern in which 6 other insiders also bought within the past 14 days, suggesting coordinated or prompted acquisition activity. iBio faces material headwinds: the company reported $0.00 in latest quarterly revenue and a net loss of $-4.0M over its most recent full fiscal year, with a market cap of only $22.7M. The purchase was made at a price that now trades $2.48 currently (down 38.9% from the 52-week high of $4.06), situating the buy in the mid-range of recent volatility but after a recent 90-day decline of -11.7%.

CFO Duran Felipe bought 9,191 shares ($25.0K) of IBIO at $2.72; holdings surge 471.8%. Six other insiders also bought in past 14 days.

CFO Duran Felipe purchased 9,191 shares at $2.72 on 2025-01-10, increasing his holdings from 1,948 to 11,139 shares—a 471.8% increase in position size. This buy is part of a broader cluster pattern, with 6 other insiders also purchasing within the past 14 days. The company is unprofitable with a $-4.0M net income over its most recent full fiscal year and zero revenue in the latest quarter, presenting a financially distressed profile. The stock currently trades at $2.48 (down 38.9% from its 52-week high of $4.06), though it has gained 7.4% over the past 30 days. The concentration of insider purchases across multiple executives warrants attention as a potential signal of valuation opportunity or material information not yet public.

iBio insider Brenner Martin purchased 9,191 shares at $2.72 on 2025-01-10; holdings doubled to 18,316 shares amid 6-insider cluster buy

Brenner Martin doubled his shareholding by purchasing 9,191 shares for $24,999.52, increasing his position from 9,125 to 18,316 shares. This transaction is part of a cluster pattern: 6 other insiders also bought within the past 14 days, suggesting coordinated confidence at the board or management level. The company faces significant headwinds—latest quarterly revenue is $0.00, net income is $-3,989,000.00, and market cap is only $22,690,685.60—making this purchase noteworthy as a signal of insider accumulation during a period of operational and financial stress. The stock is currently trading at $2.48, down 38.9% from its 52-week high of $4.06, though up 7.4% over the prior 30 days; investors should monitor whether the cluster buy activity represents confidence in a turnaround or reflects other strategic considerations.

Director Clark William D purchases 1,838 shares at $2.72; 6 other insiders bought within 14 days as IBIO stock down -38.9% from 52-week high.

Director Clark William D initiated a position of 1,838 shares at $2.72 on 2025-01-10, representing his first recorded purchase. This transaction is part of a cluster pattern in which 6 other insiders also bought within the past 14 days, suggesting coordinated or simultaneous interest despite unfavorable fundamentals. The company reported $0.00 revenue in the latest quarter and a net loss of $-4.0M, with negative full-year net income, yet multiple board members moved to acquire equity near a 52-week trough (current price $2.48 is -38.9% from the $4.06 peak). The 30-day uptrend of +7.4% suggests recent stabilization, but the 90-day decline of -11.7% underscores the downward trajectory. Investors should monitor whether this cluster accumulation reflects inside conviction about a turnaround or is a routine portfolio action by individuals with limited visibility into near-term catalysts.

Director Gary buys 9,191 shares of iBio at $2.72; joins 6 other insiders buying within 14 days despite -$4.0M net income.

Director Gary purchased 9,191 shares at $2.72 on 2025-01-10, entering a position for the first time with a $25.0K commitment. This buy occurs within a cluster of 6 other insider purchases over the same 14-day window, creating a synchronized buying pattern. The company posted revenue of $0.00 in the latest quarter and net income of -$4.0M over its most recent full fiscal year, indicating material operational challenges. The current stock price of $2.48 is -38.9% from the 52-week high, and the $22.7M market cap context suggests a microcap with significant financial headwinds—the coordinated insider buying may reflect conviction about recovery potential or valuation, but occurs against a backdrop of zero revenue and substantial losses that warrant scrutiny.